PER-002-97已完成未知
Changing the treatment of psychotic patients from Haloperidol to Olanzapine: An open-label clinical trial for assessment of Efficacy and Safety.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •-Male or female patients, from 18 to 65 years of age in Visit 1.
- •-Patients with pregnancy potential should be using a medically accepted method of contraception.
- •-Each patient must have a sufficient level of understanding to be able to communicate intelligently with the doctor, the nurse or the study coordinator.
- •-The patient must be considered reliable. They must agree to cooperate with all the tests and exams required by the protocol.
- •-Each patient (or his or her legal representative) must understand the nature of the study and must sign the informed consent.
- •-Patients must meet the criteria for schizophrenia, schizophreniform or schizoaffective disorder as defined in ICD-10 (F20.x, F23.2x, or F25.x).
- •-Patients must have been treated with haloperidol for a minimum period of 4 weeks before being included in this study.
- •-Patients must have a score on the total SAS of> 3.
排除标准
- •-The patients who are lactating or in gestation.
- •-Unstable disease, including liver, kidney, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinological, neurological, or hematological such that hospitalization could be anticipated within three months or death expected within three years.
- •-Hypothyroidism or hyperthyroidism not corrected.
- •-Acute angle glaucoma.
- •-One or more seizures without a determined etiology.
- •-Leukopenia or history of leukopenia, without clear and resolved etiology
- •-Jaundice, hepatitis B positive surface antigen (HBsAg) or detectable IgM fraction of anti-HBc antibody.
- •-History of severe allergies or multiple adverse reactions to drugs.
- •-Substance abuse or dependence (alcohol or other drugs) within the past three months.
- •-According to the researcher´s criteria, be at serious risk of suicide.
- •-Participation in a clinical study of another investigational drug within one month (30 days) before entry into this study (Visit 1).
- •-Any concomitant medication with primary activity in the central nervous system does not specify in Section 3.8.
- •-Treatment with a neuroleptic agent with less than one dose interval between neuroleptic injections before Visit 1.
- •-Previous exposure to Olanzapine.
- •-Treatment with lithium, anticonvulsants, benzodiazepines, antidepressants (except fluoxetine), psychostimulants,
- •-Reversible inhibitors of monoamine oxidase, reserpine, guanethidine or guanadrel within one week before visit 2.
- •-Any patient treated with clozapine within four weeks before visit 2.
- •-Treatment with non-reversible inhibitors of monoamine oxidase within two weeks before visit 2.
- •-Treatment with fluoxetine within four weeks before visit 2.
- •-Treatment with remoxipride within six months (180 days) before visit 2.
- •-Use of anticholinergic medication as prophylaxis is prohibited.
- •-More than 20 mg of haloperidol in the last two days before visit 2.
研究者
相似试验
招募中
不适用
Transforming treatments for schizophrenia: Virtual reality, brain stimulation and social cognition.schizoaffective disordersocial cognitionMental Health - SchizophreniaschizophreniaACTRN12621001649808Monash University46
招募中
不适用
Tailoring evidence-based psychological therapy for people with common mental disorder including psychotic experiences work package 3d: a feasibility studyMental healthMental and Behavioural DisordersISRCTN16318194Cambridgeshire and Peterborough NHS Foundation Trust45
进行中（未招募）
1 期
Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disordersSchizophrenia, schizoaffective disorders,psychosis not otherwise specified, and dellusional disordersEUCTR2021-003588-85-BECLouvain100
已完成
不适用
Mentalization-Based Treatment for Psychosis: a randomized controlled trial for outpatients with a nonaffective psychotic disorder.Non-affective psychotic disorders10039628NL-OMON44966Academisch Medisch Centrum90
招募中
不适用
Integrated care model to relieve psychotic symptoms and prevent relapse in the first-episode schizophreniaRelapse in the first-episode schizophrenia patientsFirst-episode schizophrenia,caregiversTCTR20190923001Faculty of public health, Mahasarakham University49